Lichinitser MR - Search Results

1

Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.

Diel IJ, Body JJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergström B; MF 4265 Study Group. Diel IJ, et al. Among authors: lichinitser mr. Eur J Cancer. 2004 Jul;40(11):1704-12. doi: 10.1016/j.ejca.2004.03.025. Eur J Cancer. 2004. PMID: 15251160 Clinical Trial.

2

Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer.

Body JJ, Diel IJ, Bell R, Pecherstorfer M, Lichinitser MR, Lazarev AF, Tripathy D, Bergström B. Body JJ, et al. Among authors: lichinitser mr. Pain. 2004 Oct;111(3):306-312. doi: 10.1016/j.pain.2004.07.011. Pain. 2004. PMID: 15363874 Clinical Trial.

3

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.

Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergström B; MF 4265 Study Group. Body JJ, et al. Among authors: lichinitser mr. Ann Oncol. 2003 Sep;14(9):1399-405. doi: 10.1093/annonc/mdg367. Ann Oncol. 2003. PMID: 12954579 Free article. Clinical Trial.

4

Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.

Body JJ, Lichinitser M, Tjulandin S, Garnero P, Bergström B. Body JJ, et al. Ann Oncol. 2007 Jul;18(7):1165-71. doi: 10.1093/annonc/mdm119. Epub 2007 Apr 17. Ann Oncol. 2007. PMID: 17442659 Free article. Clinical Trial.

5

Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia.

Ralston SH, Thiébaud D, Herrmann Z, Steinhauer EU, Thürlimann B, Walls J, Lichinitser MR, Rizzoll R, Hagberg H, Huss HJ, Tubiana-Hulin M, Body JJ. Ralston SH, et al. Among authors: lichinitser mr. Br J Cancer. 1997;75(2):295-300. doi: 10.1038/bjc.1997.48. Br J Cancer. 1997. PMID: 9010041 Free PMC article. Clinical Trial.

6

Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.

Robertson JF, Howell A, Gorbunova VA, Watanabe T, Pienkowski T, Lichinitser MR. Robertson JF, et al. Among authors: lichinitser mr. Breast Cancer Res Treat. 2005 Jul;92(2):169-74. doi: 10.1007/s10549-004-4776-0. Breast Cancer Res Treat. 2005. PMID: 15986127

7

[Carminomycin study in breast cancer].

Lichinitser MR, Assekritova IV, Gorbunova VA, Arseriĭ SA, Vaarik KhM. Lichinitser MR, et al. Antibiotiki. 1978 May;23(5):453-7. Antibiotiki. 1978. PMID: 350145 Clinical Trial. Russian.

8

[Carminomycin in drug combination in breast cancer and soft tissue sarcomas].

Lichinitser MR, Assekritova IV, Gorbunova VA. Lichinitser MR, et al. Antibiotiki. 1977 Oct;22(10):940-3. Antibiotiki. 1977. PMID: 411416 Russian.

9

Phase I clinical study of carminomycin: its activity against soft tissue sarcomas.

Perevodchikova NI, Lichinitser MR, Gorbunova VA. Perevodchikova NI, et al. Among authors: lichinitser mr. Cancer Treat Rep. 1977 Dec;61(9):1705-7. Cancer Treat Rep. 1977. PMID: 340034 Clinical Trial. No abstract available.

10

[Therapeutic use of carminomycin in soft tissue sarcomas].

Perevodchikova NI, Gorbunova VA, Lichinitser MR, Moroz LV. Perevodchikova NI, et al. Among authors: lichinitser mr. Antibiotiki. 1976 Jul;21(7):657-60. Antibiotiki. 1976. PMID: 782353 Clinical Trial. Russian.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

83 results

Search Page

Filters